Search clinical trials for: 131I-rituximab

Total 3402 results

Stealth BioTherapeutics Inc.

Completed

Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction

Heart Failure

Netherlands, Italy, United Kingdom
Kissei Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.

Completed

A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Anemia

Japan
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
Cancer Research UK
BioInvent International AB; Bloodwise

Completed

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

B-cell Lymphoma | Waldenström Macroglobulinemia | Chronic Lymphocytic Leukaemia

United Kingdom
Cellectar, Inc

Completed

Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors

Solid Tumors

United States
Poitiers University Hospital

Completed

Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response

Metastatic Colon Cancer

France
Cliniques universitaires Saint-Luc- Université...
Merck Sharp & Dohme LLC; Merck Serono International SA

Completed

Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery (CHIRON)

Head and Neck Cancer

Belgium
Copenhagen University Hospital at Herlev

Unknown

Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients

Rectum Cancer

Denmark
Assistance Publique - Hôpitaux de Paris
GERCOR - Multidisciplinary Oncology Cooperative Group

Completed

FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer (FOLFOX)

Esophageal Cancer Stage III

France
Nordic Lymphoma Group
AstraZeneca

Active, not recruiting

Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma (ALTAMIRA)

Mantle Cell Lymphoma | MCL

Finland, Sweden, Norway, Denmark, Korea, Republic of
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Completed

Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin | Child, Only
Asociacion Doctor Peset Para el Estudio de la Hematología
Cephalon; Pivotal S.L.

Unknown

Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk

No Hodgkin B Lymphoma

Spain
IsoRay Medical, Inc.

Withdrawn

A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer

NSCLC | Non Small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Lymphoma | Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Lymphocytic Neoplasm

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma | Liver Lymphoma

United States
Paris Cardiovascular Research Center (Inserm U970)

Not yet recruiting

Rituximab in Patients With Acute Rheumatic Fever (AGRAF-2)

Rheumatic Heart Disease in Children
Duke University
Spectrum Pharmaceuticals, Inc

Terminated

Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma

Mantle-Cell Lymphoma

United States
Heidelberg University

Completed

Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Germany
Gustave Roussy, Cancer Campus, Grand Paris

Active, not recruiting

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE)

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation

France
Merck KGaA, Darmstadt, Germany

Completed

Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) (NEXT)

Non-Small Cell Lung Cancer (NSCLC)

Germany
The Lymphoma Academic Research Organisation

Recruiting

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Marginal Zone Lymphoma

France
University Hospital, Grenoble

Terminated

Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates

Kidney Transplantation | End-stage Renal Disease | Hla-incompatible Kidney Transplant Candidates

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract

Head and Neck Cancer | Precancerous Condition

United States, Canada
University of Ulm
Pfizer; AbbVie; Ludwig-Maximilians - University of Munich; Zentrum für Klinische... and other collaborators

Not yet recruiting

Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia (VIWA-1)

Waldenstrom Macroglobulinemia
Centre Hospitalier de PAU
University Hospital, Bordeaux

Completed

Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE)

Nervous System Diseases | Multiple Sclerosis, Chronic Progressive

France
Corixa Corporation
GlaxoSmithKline

Unknown

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Corixa Corporation
GlaxoSmithKline

Unknown

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement

Non-Hodgkin's Lymphoma

United States
Assistance Publique - Hôpitaux de Paris

Terminated

Amoxicillin Susceptibility of Oral Streptococci After a 3-Day or a 7-Day Amoxicillin Therapy (ODAMOX)

Odontogenic Infection

France
Anhui Provincial Hospital

Not yet recruiting

The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT

High Titers of Anti-HLA Antibody (MFI ≥5000)

China
Fondation Ophtalmologique Adolphe de Rothschild

Not yet recruiting

Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial. (IMCOMG)

Ocular Myasthenia Gravis
Rennes University Hospital

Recruiting

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. (TRIO)

Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis

France
Georgetown University
Hackensack Meridian Health

Active, not recruiting

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

Chronic Lymphocytic Leukemia

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto
ERIC Group

Completed

Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study (LLC178)

Chronic Lymphocytic Leukemia

Italy
Zhejiang Hisun Pharmaceutical Co. Ltd.

Completed

RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (Hi-CHOP)

Diffuse Large B-cell Lymphoma
Hoffmann-La Roche

Completed

A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

Italy, Belgium, Canada, Finland, Ireland, Netherlands, Peru, Spain, United Kingdom, Venezuela, Russian Federation, Brazil, France, Poland, Israel, South Africa, Thailand, Bulgaria, Colombia, Greece, Turkey, Argentina, Saudi Arabia, Uk... and more
Asan Medical Center

Unknown

Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL

Diffuse Large B-cell Lymphoma

Korea, Republic of
Universität des Saarlandes
Spectrum Pharmaceuticals, Inc; German High-Grade Non-Hodgkin's Lymphoma Study...

Completed

OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine (OPTIMAL>60)

CD20+ Aggressive B-Cell Lymphoma

Germany
National Institute of Allergy and Infectious Diseases...
National Heart, Lung, and Blood Institute (NHLBI); Genentech, Inc.; Rho Federal... and other collaborators

Terminated

Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

Cardiac Allograft Vasculopathy | Heart Transplant Recipients

United States
University of Cagliari
Azienda Ospedaliero Universitaria di Cagliari

Recruiting

BAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rheumatoid Arthritis (PREDICT)

Rheumatoid Arthritis | Systemic Lupus Erythematosus | BLyS Polymorphism

Italy
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH); Fogarty...

Completed

Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma

HIV | Diffuse Large B-cell Lymphoma

Malawi
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402

Lymphoma
Stanford University

Completed

Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma

Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large Cell Lymphoma | Transformed Lymphoma | Other Subtypes of B-cell Lymphoma

United States
GlaxoSmithKline

Completed

Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab

Lymphoma, Non-Hodgkin
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Head and Neck Cancer

United States, Puerto Rico, South Africa
Eben Rosenthal

Terminated

Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures

Head and Neck Cancer

United States
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; National Comprehensive Cancer Network

Completed

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Squamous Cell Cancer | Head and Neck

United States
Gynecologic Oncology Group
Bristol-Myers Squibb; National Cancer Institute (NCI)

Completed

Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Cervical Cancer

United States
Centre Hospitalier of Chartres
Hospital of Chartres- France

Completed

Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR (CTXSCC)

Skin Diseases | Carcinoma, Squamous Cell

France
Institute of Hematology & Blood Diseases Hospital
Henan Cancer Hospital; Nantong University; Tianjin Medical University Second... and other collaborators

Unknown

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Primary Immune Thrombocytopenia (ITP)

China

Search clinical trials for: 131I-rituximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations